Nucala (mepolizumab) / GSK  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nucala (mepolizumab) / GSK
2005-001932-61: Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial.

Ongoing
2
60
Europe
Mepolizumab, SB-240563,
University Hospitals of Leicester
Refractory Eosinophilic Asthma.
 
 
NCT05320939: Immunological Basis for Mepolizumab Activity in COPD

Not yet recruiting
2
30
NA
Mepolizumab 100 MG
Temple University, GlaxoSmithKline
COPD
04/24
05/25
REC-SAFECAD, NCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Recruiting
2
18
RoW
Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline
Xijing Hospital
Coronary Artery Disease
09/25
03/26

Download Options